• Moxalactam disodium is a new third-generation semisynthetic, broad-spectrum, cephalosporin-like antibiotic for parenteral administration. Topical, subconjunctival, and intravenous administration provide poor concentration in the vitreous. To determine its toxicity in intra-vitreal administration, we injected comparative doses directly into the vitreous cavity of 21 rabbits. With doses of 1.25 mg or less there was no toxic damage to the retina. With a dose of 2.5 mg, early degeneration of photoreceptors was seen after three months. With higher doses (5 and 10 mg) there were major histopathologic and electroretinographic changes. These results suggest the feasibility of employing moxalactam in the treatment of acute, severe, fulminant bacterial endophthalmitis.
Fett DR, Silverman CA, Yoshizumi MO. Moxalactam Retinal Toxicity. Arch Ophthalmol. 1984;102(3):435–438. doi:10.1001/archopht.1984.01040030349036
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.